The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, improved diagnostics, growing public awareness, and ...

Respiratory Syncytial Virus is a common, contagious virus affecting the lungs and breathing passages.

While cases are climbing in China, the situation is very different from what it was when Covid-19 emerged five years ago, medical experts say. HMPV has circulated in humans for decades.

Every year, millions of people worldwide are affected by a virus that often goes unnoticed –Respiratory Syncytial Virus (RSV). Despite its widespread prevalence, many people remain unaware of what RSV ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons ...

Learn about Respiratory Syncytial Virus (RSV), its symptoms, treatment, and prevention. Get expert advice on how to protect vulnerable populations from this viral infection.

Respiratory syncytial virus (RSV): What to know, including symptoms, how to know when it’s serious, who has a high risk, treatment, prevention, and more.

The RSV vaccine can protect against respiratory syncytial virus infections, especially in infants and people at high risk.

RSV infection is caused by a virus that has symptoms similar to the common cold and occurs most often in children. Learn about the causes and treatment.

Scientists have been searching for ways to get ahead of RSV as early as 1955 when a virus was discovered in chimpanzees suffering from respiratory symptoms.